J INTS BIO Presents Interim Results from the Preclinical Study of ‘JIN-001’ in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

Ethan Seah, Vice President of J INTS BIO, is giving a poster presentation on the preclinical study of its novel oral 2nd generation HSP90 (heat shock protein 90) inhibitor ‘JIN-001’ at the ENA (EORTC-NCI-AACR) Symposium.